Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.
about
Long-acting risperidone: a review of its role in the treatment of bipolar disorder.Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection.Long-acting atypical antipsychotics: characterization of the local tissue responseWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital.Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparisonAre the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalentsEvaluation of olanzapine pamoate depot in seriously violent males with schizophrenia in the community.Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.Olanzapine pamoate for the treatment of schizophrenia.Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals.Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.A review of olanzapine pamoate.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.Atypical antipsychotics in the treatment of delirium.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence.Preparation, Characterization, and In Vivo Evaluation of Olanzapine Poly(D,L-lactide-co-glycolide) Microspheres.Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
P2860
Q33886093-AE02F547-1A14-4BD1-884D-B16A133CCB84Q34122946-2FDC2453-FEEE-41BB-A05E-ABC96F963676Q34130433-31832613-59CC-4162-825F-677F8DC78456Q34315836-4A7B7857-01DB-43D6-8F78-DA27F025CA3AQ34418833-4AA89BEE-FE46-4810-90D2-470759FB7448Q34660553-8603A84A-8706-4FE9-88C6-C01B3F788149Q34720828-FA1C6557-DE73-40C5-8119-FEC4D0953196Q35229068-B8C7763E-AFE4-4284-9677-1111AB90B4B0Q36235106-F9287356-D64F-456C-BAB0-78A2A28180DCQ37282220-32482DEA-9BE9-40AA-98A8-B39225B44CC3Q37546091-DE79D5C6-B7A0-4921-BCE1-3C50AC86E984Q37804880-6D076E8C-6161-4FC8-8DBC-DCB5556244E7Q37831310-6ECED2F8-8846-4FB7-ACA4-0136579D364AQ38010780-2448F9CC-EB0C-4FB3-BD6F-C583D9177C8BQ38013250-6C86AFD2-4AA5-4D69-AB5D-CA297C033741Q38022638-0D9ACC37-D8D4-4233-A905-D3B374248838Q38115487-1530C490-9719-4F44-9C1E-641AE60A829BQ38121987-22AC81B6-5BEC-457F-87F2-B6B58314C814Q38125213-EA0D1610-18A7-4809-9F54-80257360AEA0Q38271353-4798B4DD-FCC1-4032-8F83-22123A4920DAQ38694855-2646D3D7-A016-4EFC-ABE1-0639A7356B07Q38874076-AF6A9C00-BE49-40E3-AB37-A5A9A68F8AC2Q40335811-AB6D9D3C-6E90-4DE2-A6CA-B01D4F8C2AB6Q42279135-5473C757-6810-4037-9D6C-CD61CED150F0Q42427644-A6F9B26C-9101-45FA-87A0-C715654B9180Q42520005-65765E5E-9F51-47C6-AC52-EBE8600313DEQ54217848-8CCA008D-234C-4B79-87A6-6817C80E25B4
P2860
Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Olanzapine pamoate: a stick in ...... cond-generation antipsychotic.
@en
Olanzapine pamoate: a stick in ...... cond-generation antipsychotic.
@nl
type
label
Olanzapine pamoate: a stick in ...... cond-generation antipsychotic.
@en
Olanzapine pamoate: a stick in ...... cond-generation antipsychotic.
@nl
prefLabel
Olanzapine pamoate: a stick in ...... cond-generation antipsychotic.
@en
Olanzapine pamoate: a stick in ...... cond-generation antipsychotic.
@nl
P1476
Olanzapine pamoate: a stick in ...... cond-generation antipsychotic.
@en
P2093
P304
P356
10.1111/J.1742-1241.2008.01900.X
P577
2008-10-01T00:00:00Z